Potential Mechanism of SGLT2i Induced Euglycaemic Diabetic Ketoacidosis

MOULINATH BANERJEE

doi:10.4172/2470-7570.1000107

Potential Mechanism of SGLT2i Induced Euglycaemic Diabetic Ketoacidosis

MOULINATH BANERJEE

Medical School

University of Manchester

Research output: Contribution to journal › Comment/debate

Abstract

Sodium glucose co-transporter 2 inhibitors are a new group of drugs available to treat patients with type 2 diabetes mellitus. Recently, FDA has sounded a warning of higher risk of Diabetes ketoacidosis among patients treated with this group of agents. This article reviews the available evidence to build a potential hypothesis to explain the development of this complication.

Original language	American English
Pages (from-to)	1-2
Journal	Endocrinol Diabetes Research
Volume	1
Issue number	2
DOIs	https://doi.org/10.4172/2470-7570.1000107
Publication status	Published - 30 Aug 2015

Keywords

Sodium glucose co-transporter 2 inhibitors
Diabetic ketoacidosis
Glucagon
Insulin
Type 2 diabetes mellitus

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.4172/2470-7570.1000107

Cite this

@article{130c71e1a2b948f59eccf538a0ad3bba,

title = "Potential Mechanism of SGLT2i Induced Euglycaemic Diabetic Ketoacidosis",

abstract = "Sodium glucose co-transporter 2 inhibitors are a new group of drugs available to treat patients with type 2 diabetes mellitus. Recently, FDA has sounded a warning of higher risk of Diabetes ketoacidosis among patients treated with this group of agents. This article reviews the available evidence to build a potential hypothesis to explain the development of this complication.",

keywords = "Sodium glucose co-transporter 2 inhibitors, Diabetic ketoacidosis, Glucagon, Insulin, Type 2 diabetes mellitus",

author = "MOULINATH BANERJEE",

year = "2015",

month = aug,

day = "30",

doi = "10.4172/2470-7570.1000107",

language = "American English",

volume = "1",

pages = "1--2",

journal = "Endocrinol Diabetes Research",

issn = "2470-7570",

number = "2",

}

TY - JOUR

T1 - Potential Mechanism of SGLT2i Induced Euglycaemic Diabetic Ketoacidosis

AU - BANERJEE, MOULINATH

PY - 2015/8/30

Y1 - 2015/8/30

N2 - Sodium glucose co-transporter 2 inhibitors are a new group of drugs available to treat patients with type 2 diabetes mellitus. Recently, FDA has sounded a warning of higher risk of Diabetes ketoacidosis among patients treated with this group of agents. This article reviews the available evidence to build a potential hypothesis to explain the development of this complication.

AB - Sodium glucose co-transporter 2 inhibitors are a new group of drugs available to treat patients with type 2 diabetes mellitus. Recently, FDA has sounded a warning of higher risk of Diabetes ketoacidosis among patients treated with this group of agents. This article reviews the available evidence to build a potential hypothesis to explain the development of this complication.

KW - Sodium glucose co-transporter 2 inhibitors

KW - Diabetic ketoacidosis

KW - Glucagon

KW - Insulin

KW - Type 2 diabetes mellitus

U2 - 10.4172/2470-7570.1000107

DO - 10.4172/2470-7570.1000107

M3 - Comment/debate

SN - 2470-7570

VL - 1

SP - 1

EP - 2

JO - Endocrinol Diabetes Research

JF - Endocrinol Diabetes Research

IS - 2

ER -

Potential Mechanism of SGLT2i Induced Euglycaemic Diabetic Ketoacidosis

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this